文献速递慢性肾脏病

达格列净在慢性肾脏病中预防不良结局的随机对照试验:依据与方案

Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
PubMed 文献 · Nephrol Dial Transplant · 2020-01-01

DAPA-CKD 是一项随机、双盲、安慰剂对照试验,计划纳入约4300例CKD 2-4期且尿白蛋白排泄升高的患者,评估达格列净10 mg/日对肾脏和心血管复合终点的影响。试验将确保至少30%无糖尿病、不超过10% eGFR>60,主要终点为eGFR持续下降≥50%、终末期肾病、肾脏死亡或心血管死亡的复合终点。

要点

  • DAPA-CKD 评估达格列净在伴或不伴糖尿病的CKD患者中的肾脏和心血管获益。
  • 入组标准为尿白蛋白/肌酐比值≥200 mg/g且eGFR 25-75 mL/min/1.73 m2。
  • 主要终点为eGFR持续下降≥50%、终末期肾病、肾脏死亡或心血管死亡的复合终点。

核心结论

  • DAPA-CKD将确定达格列净在指南推荐治疗基础上是否安全降低伴或不伴糖尿病各期CKD患者的肾脏和心血管事件率。

研究设计与样本

  • 随机、双盲、安慰剂对照试验,计划纳入约4300例CKD 2-4期且尿白蛋白排泄升高的患者。
  • 入组时绝大多数患者将接受最大耐受剂量的肾素-血管紧张素系统抑制剂。
  • 筛选后,尿白蛋白/肌酐比值≥200 mg/g且eGFR 25-75 mL/min/1.73 m2的患者随机接受安慰剂或达格列净10 mg/日。
  • 监测入组以确保至少30%患者无糖尿病,且不超过10%患者eGFR>60 mL/min/1.73 m2。

主要发现

  • 近期心血管结局试验显示SGLT2抑制剂延缓高心血管风险2型糖尿病患者的CKD进展。
  • 这些获益是否延伸至不伴2型糖尿病或心血管疾病的CKD患者尚不清楚。

关键数值与推荐

  • 主要终点为eGFR持续下降≥50%、终末期肾病、肾脏死亡或心血管死亡的复合终点。
  • 试验将在发生681个主要肾脏事件时结束,提供90%把握度检测22%的相对风险降低(α水平0.05)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent cardiovascular outcome trials have shown that sodium-glucose co-transporter 2 (SGLT2) inhibitors slow the progression of chronic kidney disease (CKD) in patients with type 2 diabetes at high cardiovascular risk. Whether these benefits extend to CKD patients without type 2 diabetes or cardiovascular disease is unknown. The Dapagliflozin and Prevention of Adverse Outcomes in CKD (DAPA-CKD) trial (NCT03036150) will assess the effect of the SGLT2 inhibitor dapagliflozin on renal and cardiovascular events in a broad range of patients with CKD with and without diabetes. METHODS: DAPA-CKD is a randomized, double-blind, placebo-controlled, trial in which ∼4300 patients with CKD Stages 2-4 and elevated urinary albumin excretion will be enrolled. The vast majority will be receiving a maximum tolerated dose of a renin-angiotensin system inhibitor at enrolment. RESULTS: After a screening assessment, eligible patients with a urinary albumin:creatinine ratio ≥200 mg/g and estimated glomerular filtration rate (eGFR) between 25 and 75 mL/min/1.73 m2 are randomly assigned to placebo or dapagliflozin 10 mg/day. Enrolment is monitored to ensure that at least 30% of patients do not have diabetes and that no more than 10% have an eGFR >60 mL/min/1.73 m2. The primary endpoint is a composite of a sustained decline in eGFR of ≥50%, end-stage renal disease, renal death or cardiovascular death. The trial will conclude when 681 primary renal events have occurred, providing 90% power to detect a 22% relative risk reduction (α level of 0.05). CONCLUSION: DAPA-CKD will determine whether the SGLT2 inhibitor dapagliflozin, added to guideline-recommended therapies, safely reduces the rate of renal and cardiovascular events in patients across multiple CKD stages with and without diabetes.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Heerspink HJL, Stefansson BV, Chertow GM, et al. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. Nephrol Dial Transplant. 2020. PMID: 32030417. doi:10.1093/ndt/gfz290

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。